ARVINAS, INC. (ARVN)
$9.18-$0.06 (-0.65%) Today
Randy Teel - OfficerAndrew Saik - OfficerRandy Teel - OfficerArvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 8,272 | $66K |
| Grant or award | 12 | 229,446 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
34 Form 4 filings on record, the earliest from Nov 12, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David K. Loomis - Officer | Open-market sale | Common Stock | 1,016 | $11.89 | $12K | |
| David K. Loomis - Officer | Open-market sale | Common Stock | 230 | $9.89 | $2K | |
| Briggs Morrison - Director | Open-market purchase | Common Stock | 30,000 | $7.57 | $227K | |
| David K. Loomis - Officer | Open-market sale | Common Stock | 229 | $17.05 | $4K | |
| David K. Loomis - Officer | Open-market sale | Common Stock | 231 | $27.69 | $6K |
This is as far as the anonymous view goes. Create a free account for all 34 ARVN filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| NOAH C BERKOWITZ | Officer | 30,000 | $264K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
ARVINAS, INC. (ARVN) had 8 insider filings in the last 90 days, with the most recent on 2026-06-26. The full record for ARVN runs to 34 Form 4 filings, the earliest from 2024-11-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ARVN were filed in the last 90 days. 2 purchases are on record for this company.
2 insider sales of ARVN were filed in the last 90 days, totaling $66K.
This page tracks ARVN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ARVN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
